Keywords: BioSante Pharma, GVAX Prostate, USA, FDA, Clinical hold, Dendreon, Provenge

US FDA lifts clinical hold on BioSante GVAX prostate cancer vaccine

Article | 8 June 2011

Print This

BioSante Pharmaceuticals (Nasdaq: BPAX) says that the US Food and Drug Administration’s clinical hold on the GVAX Prostate ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in